ABOUT STANDARD BARIATRICS®
Standard Bariatrics, Inc., is a Cincinnati-based company focused on the development and commercialization of medical devices for the surgical treatment of obesity. Driven by a passionate group of surgical innovators, the company works hand in hand with bariatric surgeons to develop and release novel solutions designed to address the growing global epidemic of obesity. The Standard Bariatrics team offers extensive experience in creating and bringing to market bariatric-related medical device technologies. They have a demonstrated record of achieving clinical excellence with economically responsible solutions for providers and their patients.
Standard Bariatrics is dedicated to bringing to market a portfolio of surgical solutions for sleeve gastrectomy. Our products are designed to work together to help surgeons elevate their individual techniques so they can achieve repeatable and consistent outcomes and reduce the cost of care.
We seek to offer bariatric surgeons the new standard in sleeve gastrectomy surgical solutions. By harmonizing techniques through product innovation and quality improvement we will enable improved outcomes of the sleeve gastrectomy procedure. With improved outcomes, surgery will become the preferred treatment modality for both patients and referring physicians.
JONATHAN THOMPSON, MD
Founder & Chief Medical Officer
Dr. Thompson practices general and bariatric surgery at University of Cincinnati (UC) Health. He is an assistant professor at the UC College of Medicine and currently serves as Information Technology & Quality Improvement Officer – UC Health Weight Loss Center. In 2013, Dr. Thompson established and became director of The Thompson Center at the University of Cincinnati Research Institute. He also had fellowships at the University of Missouri Biodesign and Innovation Program (MUBIP) in 2009 and at the Fogarty Institute for Innovation in 2013.
President & Chief Executive Officer
Mr. Sokany has 35 years of experience in the medical device market. He has spent 24 years with Ethicon and Ethicon Endo-Surgery in various roles of increasing responsibility in sales and marketing, including serving as a US Board Member of Ethicon Endo-Surgery. Mr. Sokany has spent eight years in the medical device startup industry delivering significant investor return highlighted by the successful launch and exit of New Wave Surgical to Covidien (now Medtronic).
Chief Operating Officer
Mr. Dunki-Jacobs has over 15 years of medical device experience in several phases of product development including: academic research, front-end market creation, design, manufacturing, and post market surveillance. While working for Ethicon Endo-Surgery (a Johnson & Johnson company), he managed a research collaborative with two academic institutions focused on deconstructing metabolic changes that occur following bariatric surgery and investigated novel weight loss therapies/devices. As a design engineer at Ethicon Endo-Surgery, Mr. Dunki-Jacobs helped develop four stapling products, led the open mechanical (stapling) IP portfolio strategy, attended the University of Cincinnati as a PhD candidate investigating a novel framework for optimizing stapleline performance in tissue specific applications, and advised R&D stapling project teams as a design reviewer and subject matter expert (SME) in staple formation technology. Prior to joining Standard Bariatrics, Mr. Dunki-Jacobs was the Director of Engineering at Enable Injections (a clinical stage startup company located in Cincinnati, OH) where he led the design and development of a novel drug delivery device. Since joining Standard Bariatrics in 2016, Mr. Dunki-Jacobs was responsible for leading the development of the STANDARD CLAMP® and TITAN SGS™ products. Mr. Dunki-Jacobs holds more than 100 published U.S. patents and applications in medical devices; with more than 70 of those in stapling technology.
Chief Commercial Officer
Mr. Galovich holds 30 years of extensive experience in the medical device and life science industries developing and leading global commercial organizations. He has held senior commercial leadership positions in sales, marketing and general management within organizations such as Ethicon, a Johnson & Johnson company, Tyco Healthcare (now Medtronic), Zimmer Biomet, Baxter, and Steris. Mr. Galovich has extensive global concept-commercialization experience, having launched numerous novel and disruptive technologies in general surgery, minimally invasive surgery, cardiovascular surgery, orthopedic surgery, women’s health, and infection prevention.
Chief Financial Officer
Mr. Donato joined Standard Bariatrics as CFO in May 2020, bringing nearly three decades of experience including more than 17 years of senior leadership in healthcare. Notable companies where he served include Genetesis, where he was president and board director leading early financing, reimbursement, and commercialization efforts. As CFO at Assurex Global, Mr. Donato co-led its sale to Myriad, and while CFO at Neuronetics, led its initial public offering. Having started his career with Ernst & Young, General Motors, and Scott’s Miracle Gro, he moved on to Bovie Medical, Cyberonics and Iris. Mr. Donato earned his bachelor’s degree in business administration and accounting from The Fisher School of Business at The Ohio State University and his MBA from the University of Akron. Mr. Donato is a licensed CPA.
BOARD OF DIRECTORS
Mr. Azarbarzin brings a highly experienced background including nearly 40 years in advanced surgical technology companies to the board. He currently serves as CEO at ColubrisMX, the pioneering developer of endoluminal and single-port robotic platforms. Previously, Mr. Azarbarzin was the global head of digital science/robotics at Ethicon following his appointment as the president and chief executive officer of Verb Surgical Robotics, Inc., the joint venture between Google and Johnson & Johnson which was acquired by J&J in late 2019. Mr. Azarbarzin was founder and chief executive officer of venture-backed SurgiQuest, Inc., a medical device company focused on minimally invasive surgery that was acquired for $265 million by CONMED Corporation in January 2016. Prior to SurgiQuest, he spent 21 years at US Surgical Corporation/Tyco Healthcare, most recently as global vice president of research and development. Mr. Azarbarzin also serves a member of the board at TELA Bio, Inc., and is a member of the executive board at the Center for Biomedical Innovation and Technology at Yale University.
JONATHAN THOMPSON, MD
Founder & Chief Medical Officer
Dr. Thompson practices general and bariatric surgery at UC Health. He is an assistant professor at the University of Cincinnati College of Medicine and currently serves as information technology and quality improvement officer at the UC Health Weight Loss Center. In 2013 Dr. Thompson established and became director of The Thompson Center at the University of Cincinnati Research Institute. He had fellowships at the University of Missouri Biodesign and Innovation Program (MUBIP) in 2009 and the Fogarty Institute for Innovation in 2013.
Mr. Sokany holds 35 years of experience in the medical device market. He spent 24 years with Ethicon and Ethicon Endo-Surgery in various roles of increasing responsibility in sales and marketing, including serving as US board member of Ethicon Endo-Surgery. Mr. Sokany has spent eight years in the medical device startup industry delivering significant investor return highlighted by the successful launch and exit of New Wave Surgical to Covidien (now Medtronic).
Karen Spilizewski is a vice president with RiverVest Venture Partners. Ms Spilizewski brings broad knowledge of the seed and early-stage life science opportunity landscape in the Midwest, and the ability to source and evaluate the most promising deals. Through her product and business development expertise, she helps entrepreneurs accelerate their companies toward next development milestones. Ms Spilizewski is also a vice president of BioEnterprise Corporation in Cleveland, where she directs business development for medical device and equipment companies.
DOUGLAS REED, MD
Douglas Reed, MD, is a general partner with Hatteras Venture Partners based in Durham, NC. Hatteras invests in early-stage biotechnology and medical technology companies with an emphasis on new company formation in the southeastern United States. The firm currently has over $450 million under management and has invested in more than 50 companies to date. He currently serves on the board of directors of Contego Medical, Innocrin Pharmaceuticals, NeuroTronik, Standard Bariatrics, Viamet Pharmaceuticals, and SEBIO (Southeastern BIO). He is chairman of the board of Innocrin and served on the board of Embrella Cardiovascular prior to its acquisition by Edwards Lifesciences. Dr. Reed trained in interventional radiology and neuroradiology and held academic appointments in the Department of Radiology at the University of Washington and at Yale University School of Medicine. He earned B.A. and M.D. degrees at the University of Missouri – Kansas City and an M.B.A. in finance and healthcare administration from The Wharton School at the University of Pennsylvania. He completed residency training in Diagnostic Radiology at the University of Washington and a fellowship in neuroradiology at the University of British Columbia.
Casey Tansey joined USVP as a General Partner in April of 2005. A veteran of the medical device industry, Casey brings over 30 years of entrepreneurial, early stage medical device and seasoned operating experience to USVP. At USVP, Casey focuses on the trend toward miniaturization of devices and the development of minimally-invasive technologies that promise innovations in the delivery of medical products and services, especially in cardiovascular products, sleep apnea, ENT and vascular. Prior to joining USVP, Casey served as the CEO and President of Epicor Medical from 2001 to 2004. Casey, along with a dedicated team, pioneered a minimally-invasive treatment for atrial fibrillation. He led Epicor’s acquisition by St. Jude Medical. Prior to Epicor, Casey was CEO and President of Heartport, a public company that helped pioneer minimally-invasive cardiac surgery which is now a Johnson & Johnson company. Before that, he was with Baxter Edward’s Cardiovascular Division for nearly ten years, holding various sales and marketing positions. During his tenure at Baxter, Casey was involved in launching innovative heart valve products that have grown to be the market leaders. Casey's recent board activities have included Inspire Medical (IPO), IntersectENT (IPO), AtheroMed (sold to Volcano), Nanostim (sold to St. Jude Medical) and SentreHeart (sold to AtriCure). Currently, he serves on the Board of Directors for Dstillery, HeartFlow, Highlife Medical, Intuity Medical, NeoChord, Neuros Medical, PlaceIQ, Shiratronics, Shoulder Innovations and Standard Bariatrics. Casey also served as the Chairman of the Board of Directors of the World Heart Foundation, an organization dedicated to advancing humanitarian efforts in heart surgery worldwide through education and collaboration. Casey holds a B.S. and M.B.A. from the College of Notre Dame in Belmont, CA.
SCIENTIFIC ADVISORY BOARD
John Morton, MD, MPH, FACS, FASMBS
Yale School of Medicine
Past-President, American Society for Metabolic
and Bariatric Surgery 2014-2015
Helmuth Billy, MD
Thomas Inge, MD, PhD
Children’s Hospital Colorado
Brad Watkins, MD, FACS, FASMBS
Paul Enochs, MD, FACS, FASMBS